BMY · Bristol Myers Squibb Co · Financials

$59.12 -0.46 (-0.77%) At close · Oct 9

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$120.77B

2.04B

Volume · Oct 9 9.25M Avg daily vol (3M) 11.27M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$48.19B -0.2%

FY2025

Net Income

$7.05B +178.8%

FY2025

Gross Margin

72.31% +3.2pp

FY2020

Diluted EPS

$3.46 +178.5%

FY2025

Operating Cash Flow

$14.16B -6.8%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+1.4%	+2.5%	+11.3%	$49B – $50B*	$49.19B	$48.19B	$48.3B	$45.01B	$46.16B^G	$46.39B	$42.52B	$26.15B	$22.56B	$20.78B	$19.43B	$16.56B	$15.88B	$16.39B	$17.62B	$21.24B	$19.48B	$18.81B	$17.72B	$15.62B
Cost of Revenue	+11.2%	+3.4%	+13.6%	—	$14.68B	$13.94B	$13.97B	$10.69B	$10.14B	$9.94B	$11.77B	$8.08B	$6.47B	$6.01B	$4.97B	$3.91B	$3.93B	$4.62B	$4.61B	$5.6B	$5.28B	$5.14B	$5.32B	$4.92B
Gross Profit	+27.9%	+19.4%	+8.0%	—	—	—	—	—	—	—	$30.75B	$18.07B	$16.09B	$14.68B	$14.48B	$12.65B	$11.95B	$11.77B	$13.01B	$15.65B	$14.21B	$13.67B	—	—
Gross Margin	—	—	—	—	—	—	—	—	—	—	72.31%	69.1%	71.34%	70.67%	74.54%	76.39%	75.24%	71.81%	73.84%	73.65%	72.92%	72.67%	—	—
Research & Development	+1.5%	-0.2%	+5.3%	—	$10.72B	$9.95B	$11.16B	$9.3B	$9.51B	$10.2B	$10.05B	$6.15B	$6.33B	$6.47B	$5.01B	$5.92B	$4.53B	$3.73B	$3.9B	$3.84B	$3.57B	$3.65B	$3.51B	$3.16B
Selling, General & Administrative	-2.4%	-1.1%	+4.1%	—	$7.41B	$7.27B	$8.41B	$7.77B	$7.81B	$7.69B	$7.66B	$4.87B	$4.55B	$4.75B	$4.98B	$4.84B	$4.82B	$4.94B	$4.22B	$4.2B	$3.69B	$3.95B	$4.14B	$3.94B
Amortization of Intangibles	-28.8%	-18.8%	+34.3%	—	$2.72B	$3.5B	$9B	$9.2B	$9.7B	$10.2B	$9.9B	$1.3B	$198M	$190M	$178M	$183M	$286M	$858M	$607M	$353M	$271M	-$170M	—	—
Depreciation & Amortization	-26.9%	-17.3%	+26.7%	—	$3.18B	$4.01B	$9.6B	$9.76B	$10.28B	$10.69B	$10.38B	$1.75B	$637M	$789M	$382M	$376M	$467M	$763M	$681M	$628M	$607M	—	—	—
Restructuring Charges	+95.8%	+1.2%	+16.9%	—	$268M	$563M	$635M	$365M	$75M	$169M	$530M	$301M	$131M	$293M	$109M	$118M	$163M	$226M	$174M	$116M	$113M	$136M	$215M	$180M
Total Costs & Expenses	+0.4%	-4.7%	+10.4%	—	$37.28B	$38.87B	$56.68B	$36.57B	$38.45B	$38.29B	$49.39B	$21.17B	$16.59B	$15.65B	$13.51B	$14.48B	$13.5B	$13.49B	$15.28B	$14.26B	$13.41B	$13.21B	$12.94B	$13.09B
Interest Expense	+15.4%	+5.9%	+26.2%	—	$1.73B	$1.89B	$1.95B	$1.17B	$1.23B	$1.33B	$1.42B	$656M	$183M	$196M	$167M	$184M	$203M	$199M	$182M	$145M	$145M	$184M	$310M	—
Interest Income	+50.8%	+37.1%	+19.2%	—	$514M	$586M	$478M	$449M	$171M	$39M	$121M	$464M	$173M	$126M	$97M	$101M	$101M	$104M	$106M	$91M	$75M	$54M	$130M	—
Other Non-Operating Income	—	—	—	—	$188M	-$674M	-$893M	$1.16B	-$576M	$720M	$2.31B	-$938M	$854M	$1.69B	$1.45B	$187M	-$210M	-$205M	$80M	$334M	$93M	$381M	-$22M	-$77M
Equity in Earnings of Unconsolidated Entities	—	-8.2%	-5.5%	—	$178M	$47M	$44M	-$38M	-$108M	$231M	$72M	-$85M	$93M	$75M	$77M	$83M	$107M	$166M	$183M	$281M	$313M	$550M	$617M	$524M
Investment Income (Loss)	—	-25.6%	—	—	$628M	$280M	$16M	-$160M	-$801M	$745M	$1.23B	—	—	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	+6.5%	—	+16.2%	—	$11.91B	$9.33B	-$8.38B	$8.44B	$7.71B	$8.1B	-$6.87B	$4.98B	$5.97B	$5.13B	$5.92B	$2.08B	$2.38B	$2.89B	$2.34B	$6.98B	$6.07B	$5.6B	$4.78B	$2.52B
Income Tax	+18.4%	+1.4%	+17.7%	—	$2.63B	$2.27B	$554M	$400M	$1.37B	$1.08B	$2.12B	$1.52B	$1.02B	$4.16B	$1.41B	$446M	$352M	$311M	-$161M	$1.72B	$1.56B	$1.18B	$1.09B	$471M
Net Income	+3.7%	—	+16.2%	—	$9.28B	$7.05B	-$8.95B	$8.03B	$6.33B	$6.99B	-$9.02B	$3.44B	$4.92B	$1.01B	$4.46B	$1.57B	$2B	$2.56B	$1.96B	$3.71B	$3.1B	$10.61B	$5.25B	$2.17B
Net Margin	—	—	—	—	—	14.64%	-18.53%	17.83%	13.71%	15.08%	-21.2%	13.15%	21.81%	4.85%	22.94%	9.45%	12.62%	15.64%	11.12%	17.46%	15.92%	56.42%	29.62%	13.86%
Net Income Attributable to Noncontrolling Interests	-5.0%	—	-28.8%	—	—	—	—	—	$18M	$20M	$20M	$21M	$27M	-$32M	$50M	$66M	$25M	$17M	$541M	$1.55B	$1.41B	$1.25B	$996M	$763M
Net Income Available to Common Stockholders	-18.5%	-28.3%	—	—	$1.79B	—	—	—	—	—	—	—	—	—	—	—	$2B	$2.56B	$1.96B	$3.7B	$3.09B	$10.55B	—	—
Comprehensive Income	+2.3%	—	+16.1%	—	$9.54B	$6.77B	-$8.64B	$7.76B	$6.31B	$7.57B	-$9.33B	$4.68B	$4.76B	$1.22B	$4.42B	$1.52B	$1.72B	$3.62B	$1.81B	$3.03B	$3.27B	$10.78B	$3.99B	$2.35B
EPS (Basic) USD/shares	+5.3%	—	+14.0%	—	$4.55	$3.47	-$4.41	$3.88	$2.97	$3.15	-$3.99	$2.02	$3.01	$0.61	$2.67	$0.94	$1.21	$1.56	$1.17	$2.18	$1.80	$5.35	$2.64	$1.09
EPS (Diluted) USD/shares	+5.5%	—	+14.0%	$6.75 – $7.00*	$4.55	$3.46	-$4.41^G	$3.86^G	$2.95^G	$3.12^G	-$3.99	$2.01	$3.01	$0.61	$2.65	$0.93	$1.20	$1.54	$1.16	$2.16	$1.79	$5.34	$2.62	$1.09
Shares Outstanding (Basic Avg) shares	-1.5%	-2.1%	+2.0%	—	—	2.03B	2.03B	2.07B	2.13B	2.22B	2.26B	1.71B	1.63B	1.65B	1.67B	1.67B	1.66B	1.64B	1.67B	1.7B	1.71B	1.97B	—	—
Shares Outstanding (Diluted Avg) shares	-1.7%	-2.0%	+2.0%	—	—	2.04B	2.03B	2.08B	2.15B	2.25B	2.26B	1.71B	1.64B	1.65B	1.68B	1.68B	1.67B	1.66B	1.69B	1.72B	1.73B	1.98B	—	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $35.94B in buybacks, $59.26B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current debt and lease obligations	2026-06-30	USD 1,027,000,000	10-Q filed 2026-07-30
Current operating lease liabilities	2026-06-30	USD 207,000,000	10-Q filed 2026-07-30
Long-term debt, including current maturities	2026-06-30	USD 42,861,000,000	10-Q filed 2026-07-30
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of long-term debt USD 768,000,000 Noncurrent debt carrying amount USD 42,093,000,000
Noncurrent operating lease liabilities	2026-06-30	USD 1,726,000,000	10-Q filed 2026-07-30
Short-term borrowings	2026-06-30	USD 1,027,000,000	10-Q filed 2026-07-30
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Short-term bank loans and notes payable USD 259,000,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

3.15×

Peer median 6.82×

EV/EBIT

—

P/E (TTM)

12.99×

Peer median 38.39×

Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 13 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$33,279,000,000	$34,105,000,000	$31,210,000,000	$31,500,000,000	$29,214,000,000	$26,577,000,000	$15,342,000,000	$12,586,000,000
Non Us	$13,828,000,000	$13,199,000,000	$13,097,000,000	$13,825,000,000	—	—	—	—
Other Region	$1,087,000,000	$996,000,000	$699,000,000	$834,000,000	$852,000,000	$631,000,000	$524,000,000	$584,000,000
International	—	—	—	—	$16,319,000,000	$15,310,000,000	$6,266,000,000	$5,658,000,000
Rest of World	—	—	—	—	—	—	$4,013,000,000	$3,733,000,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Sales Revenue Gross	$88,085,000,000	$83,671,000,000	$73,679,000,000	$69,633,000,000	$67,897,000,000	$60,016,000,000	—	—
Net Product Sales	$46,756,000,000	$46,778,000,000	$43,778,000,000	$44,671,000,000	$45,055,000,000	$41,321,000,000	—	—
Growth Brands	$26,409,000,000	$22,563,000,000	$19,366,000,000	$16,757,000,000	—	—	—	—
Legacy Brands	$21,785,000,000	$25,737,000,000	$25,640,000,000	$29,402,000,000	—	—	—	—
Eliquis	$14,443,000,000	$13,333,000,000	$12,206,000,000	$11,789,000,000	$10,762,000,000	$9,168,000,000	$7,929,000,000	$6,438,000,000
Opdivo	$10,049,000,000	$9,304,000,000	$9,009,000,000	$8,249,000,000	$7,523,000,000	$6,992,000,000	$7,204,000,000	$6,735,000,000
Orencia	$3,705,000,000	$3,682,000,000	$3,601,000,000	$3,464,000,000	$3,306,000,000	$3,157,000,000	$2,977,000,000	$2,710,000,000
Revlimid	$2,951,000,000	$5,773,000,000	$6,097,000,000	$9,978,000,000	$12,821,000,000	$12,106,000,000	$1,299,000,000	$0
Yervoy	$2,900,000,000	$2,530,000,000	$2,238,000,000	$2,131,000,000	$2,026,000,000	$1,682,000,000	$1,489,000,000	$1,330,000,000
Pomalyst Imnovid	$2,733,000,000	$3,545,000,000	$3,441,000,000	$3,497,000,000	$3,332,000,000	$3,070,000,000	$322,000,000	$0
Reblozyl	$2,327,000,000	$1,773,000,000	$1,008,000,000	$717,000,000	$551,000,000	$274,000,000	$0	$0
Other Growth Brands	$1,924,000,000	$1,643,000,000	$1,212,000,000	$1,092,000,000	—	—	—	—
Alliance and Other Revenues	$1,438,000,000	$1,522,000,000	$1,228,000,000	$1,488,000,000	$1,330,000,000	$1,197,000,000	—	—
Breyanzi	$1,358,000,000	$747,000,000	$364,000,000	$182,000,000	$87,000,000	$0	$0	—
Opdualag	$1,185,000,000	$928,000,000	$627,000,000	$252,000,000	$0	$0	—	—
Camzyos	$1,068,000,000	$602,000,000	$231,000,000	$24,000,000	$0	$0	—	—
Other Revenues	$992,000,000	$1,043,000,000	$620,000,000	$746,000,000	$614,000,000	$582,000,000	—	—
Other Legacy Brands	$798,000,000	$925,000,000	$962,000,000	$1,162,000,000	—	—	—	—
Zeposia	$577,000,000	$566,000,000	$434,000,000	$250,000,000	$134,000,000	$12,000,000	$0	$0
Sprycel	$493,000,000	$1,286,000,000	$1,930,000,000	$2,165,000,000	$2,117,000,000	$2,140,000,000	$2,110,000,000	$2,000,000,000
Alliance Revenues	$447,000,000	$479,000,000	$608,000,000	$742,000,000	$716,000,000	$615,000,000	—	—
Abecma	$427,000,000	$406,000,000	$472,000,000	$388,000,000	$164,000,000	$0	$0	—
Abraxane	$368,000,000	$875,000,000	$1,004,000,000	$811,000,000	$1,181,000,000	$1,247,000,000	$166,000,000	$0
Sotyktu	$291,000,000	$246,000,000	$170,000,000	$8,000,000	$0	$0	—	—
Opdivo Ovantig	$238,000,000	$0	$0	—	—	—	—	—
Krazati	$205,000,000	$126,000,000	$0	$0	—	—	—	—
Cobenfy	$155,000,000	$10,000,000	$0	$0	—	—	—	—
Augtyro	—	$38,000,000	$1,000,000	$0	$0	—	—	—
Baraclude	—	—	—	—	—	$447,000,000	—	$744,000,000
Empliciti	—	—	—	$296,000,000	$334,000,000	$381,000,000	$357,000,000	$247,000,000
In Line Products and New Product Portfolio	—	—	$37,905,000,000	$35,370,000,000	$32,383,000,000	—	—	—
In Line Products	—	—	$34,320,000,000	$33,340,000,000	$31,300,000,000	—	—	—
Inrebic	—	—	$110,000,000	$85,000,000	$74,000,000	$55,000,000	$5,000,000	$0
LOE Products	—	—	$7,101,000,000	$10,789,000,000	$14,002,000,000	—	—	—
Mature Products and All Other	—	—	$1,895,000,000	$2,045,000,000	$2,234,000,000	$2,217,000,000	$2,287,000,000	$2,357,000,000
New Product Portfolio	—	—	$3,585,000,000	$2,030,000,000	$1,083,000,000	—	—	—
Onureg	—	—	$168,000,000	$124,000,000	$73,000,000	$17,000,000	$0	$0
Vidaza	—	—	—	—	—	$455,000,000	—	$0

Key facts CIK 14272 CUSIP 110122108 13F (30d) 191 filings 147 filers Visit website Investor relations